Communiqués Verrica Pharmaceuticals Inc.

Actions

VRCA

US92511W1080

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 11/06/2024			Varia. 5j.	Varia. 1 janv.
8,93 ^USD	+4,32 %		+7,46 %	+21,99 %

15/05	Verrica Pharmaceuticals modifie son accord de licence avec Torii Pharmaceutical pour l'essai de phase 3 d'Ycanth	MT
15/05	Verrica Pharmaceuticals Inc. annonce la modification de l'accord de collaboration et de licence avec Torii Pharmaceutical Co. Ltd. pour financer un essai clinique pivot de phase 3 à l'échelle mondiale afin d'étudier Ycanth pour le traitement des verrues communes	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York	30/05	GL
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York	30/05	AQ
Lytix Biopharma Q1 2024 results - Promising clinical progress with important upcoming milestones	30/05	AQ
Verrica Pharmaceuticals : Company Presentation	15/05	PU
Verrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts	15/05	GL
Verrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts	15/05	AQ
Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results	13/05	GL
Verrica Pharmaceuticals to Present at Upcoming Investor Conferences	09/05	GL
Verrica Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 13, 2024	08/05	GL
Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference	02/04	GL
Verrica Pharmaceuticals Announces that YCANTH Receives New Chemical Entity Status and Orange Book Listing from the FDA	27/03	AQ
Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA	26/03	GL
VERRICA PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA	09/03	BU
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results	29/02	GL
Verrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conference	27/02	GL
Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024	22/02	GL
Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024	22/02	AQ
VERRICA PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA	14/02	BU
Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer for False Advertising and Unfair Competition	05/02	GL
Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer for False Advertising and Unfair Competition	05/02	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Verrica Pharmaceuticals Inc.

Actions

VRCA

US92511W1080

Communiqués

Filtres